The urokinase plasminogen activator system as a target for prognostic studies in breast cancer

div class=trans-pagebuttonPage 1button div class=trans-image a href=https:reader038fdokumencomreader038viewer20230316126326adbd925f5d73fa0763b7html5page1jpg target=_blank amp-img class=trans-thumb alt=Page 1: The urokinase plasminogen activator system as a target for prognostic studies in breast cancer src=https:reader038fdokumencomreader038viewer20230316126326adbd925f5d73fa0763b7html5thumbnails1jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=trans-pagebuttonPage 2button div class=trans-image a href=https:reader038fdokumencomreader038viewer20230316126326adbd925f5d73fa0763b7html5page2jpg target=_blank amp-img class=trans-thumb alt=Page 2: The urokinase plasminogen activator system as a target for prognostic studies in breast cancer src=https:reader038fdokumencomreader038viewer20230316126326adbd925f5d73fa0763b7html5thumbnails2jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=trans-pagebuttonPage 3button div class=trans-image a href=https:reader038fdokumencomreader038viewer20230316126326adbd925f5d73fa0763b7html5page3jpg target=_blank amp-img class=trans-thumb alt=Page 3: The urokinase plasminogen activator system as a target for prognostic studies in breast cancer src=https:reader038fdokumencomreader038viewer20230316126326adbd925f5d73fa0763b7html5thumbnails3jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=trans-pagebuttonPage 4button div class=trans-image a href=https:reader038fdokumencomreader038viewer20230316126326adbd925f5d73fa0763b7html5page4jpg target=_blank amp-img class=trans-thumb alt=Page 4: The urokinase plasminogen activator system as a target for prognostic studies in breast cancer src=https:reader038fdokumencomreader038viewer20230316126326adbd925f5d73fa0763b7html5thumbnails4jpg width=142 height=106 layout=responsive amp-imga divdivdiv class=trans-pagebuttonPage 5button div class=trans-image a href=https:reader038fdokumencomreader038viewer20230316126326adbd925f5d73fa0763b7html5page5jpg target=_blank...

The urokinase plasminogen activator system as a target for prognostic studies in breast cancer

Documents

Transcript of The urokinase plasminogen activator system as a target for prognostic studies in breast cancer

Tissue plasminogen activator and urokinase plasminogen activator in human epileptogenic pathologies

Expression of plasminogen activator inhibitor‐1 and protease nexin‐1 in human astrocytes: Response to injury‐related factors

Role of plasminogen activation in neuronal organization and survival

Activated Protein C Analog Protects From Ischemic Stroke and Extends the Therapeutic Window of Tissue-Type Plasminogen Activator in Aged Female Mice and Hypertensive Rats

Impact of tissue plasminogen activator on the neurovascular unit: from clinical data to experimental evidence

TISSUE INHIBITOR OF METALLOPROTEINASE 1, MATRIX METALLOPROTEINASE 9, ALPHA1 ANTITRYPSIN, METALLOTHIONEIN AND UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTOR IN SKIN BIOPSIES FROM PATIENTS

Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions

Identification of prolylcarboxypeptidase as the cell matrix-associated prekallikrein activator

Very Low Density Lipoprotein-Mediated Signal Transduction and Plasminogen Activator Inhibitor Type 1 in Cultured HepG2 Cells

Tissue plasminogen activator is required for the growth, invasion, and angiogenesis of pancreatic tumor cells

Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones

Basic fibroblast growth factor-induced activation of latent transforming growth factor beta in endothelial cells: regulation of plasminogen activator activity

Transcriptional activation of the urokinase receptor gene in invasive colon cancer

Characterization of heme as activator of Toll-like receptor 4

Soluble Urokinase plasminogen activator receptor (suPAR) for assessment of disease severity in ventilator-associated pneumonia and sepsis

R Plasminogen in cerebrospinal fluid originates from circulating blood

Urokinase-type Plasminogen Activator-like Proteases in Teleosts Lack Genuine Receptor-binding Epidermal Growth Factor-like Domains

Liver Cirrhosis Is Reverted by Urokinase-Type Plasminogen Activator Gene Therapy

Requirement of TRAP/Mediator for Both Activator-Independent and Activator-Dependent Transcription in Conjunction with TFIID-Associated TAFIIs

Characterisation of urokinase plasminogen activator receptor variants in human airway and peripheral cells